Canada
· Delayed Price · Currency is CAD Fennec Pharmaceuticals Statistics
Total Valuation
TSX:FRX has a market cap or net worth of CAD 256.27 million. The enterprise value is 245.85 million.
| Market Cap | 256.27M |
| Enterprise Value | 245.85M |
Important Dates
The last earnings date was Thursday, March 27, 2025.
| Earnings Date | Mar 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.71% |
| Shares Change (QoQ) | +0.33% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 14.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -391.89 |
| EV / Sales | 3.62 |
| EV / EBITDA | 47.80 |
| EV / EBIT | 67.00 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.38
| Current Ratio | 6.38 |
| Quick Ratio | 5.71 |
| Debt / Equity | n/a |
| Debt / EBITDA | 5.37 |
| Debt / FCF | n/a |
| Interest Coverage | 0.62 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 4.47% |
| Return on Invested Capital (ROIC) | 9.79% |
| Return on Capital Employed (ROCE) | 6.75% |
| Revenue Per Employee | 2.14M |
| Profits Per Employee | -19,604 |
| Employee Count | 29 |
| Asset Turnover | 1.32 |
| Inventory Turnover | 1.98 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.38% in the last 52 weeks. The beta is 0.36, so TSX:FRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.36 |
| 52-Week Price Change | -35.38% |
| 50-Day Moving Average | 9.34 |
| 200-Day Moving Average | 8.15 |
| Relative Strength Index (RSI) | 42.63 |
| Average Volume (20 Days) | 731 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 18.61 |
Income Statement
In the last 12 months, TSX:FRX had revenue of CAD 68.40 million and -627,334 in losses. Loss per share was -0.03.
| Revenue | 68.40M |
| Gross Profit | 63.82M |
| Operating Income | 3.69M |
| Pretax Income | -102,158 |
| Net Income | -627,334 |
| EBITDA | 5.18M |
| EBIT | 3.69M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 38.32 million in cash and 27.83 million in debt, giving a net cash position of 10.49 million.
| Cash & Cash Equivalents | 38.32M |
| Total Debt | 27.83M |
| Net Cash | 10.49M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -8.45M |
| Book Value Per Share | -0.31 |
| Working Capital | 53.53M |
Cash Flow
| Operating Cash Flow | 38.82M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 93.30%, with operating and profit margins of 5.40% and -0.92%.
| Gross Margin | 93.30% |
| Operating Margin | 5.40% |
| Pretax Margin | -0.15% |
| Profit Margin | -0.92% |
| EBITDA Margin | 7.57% |
| EBIT Margin | 5.40% |
| FCF Margin | n/a |
Dividends & Yields
TSX:FRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.71% |
| Shareholder Yield | -2.71% |
| Earnings Yield | -0.24% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on September 5, 2014. It was a reverse split with a ratio of 0.3333333.
| Last Split Date | Sep 5, 2014 |
| Split Type | Reverse |
| Split Ratio | 0.3333333 |
Scores
TSX:FRX has an Altman Z-Score of -2.26. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.26 |
| Piotroski F-Score | n/a |